Related Experiment Videos
[Bipolar disorder: clinical trials with fluoxetine]
L A Ambrosio1, D Buccomino, A Filippo
1Servizio di Psichiatria, Ospedale Civile Dell'Annunziata, Cosenza.
Minerva Psichiatrica
|October 1, 1992
Summary
Fluoxetine treatment effectively reduced depressive symptoms in 70% of bipolar disorder patients over 8 weeks. The medication demonstrated good tolerability with mild side effects, suggesting its efficacy for bipolar depression.
Area of Science:
- Psychiatry
- Pharmacology
Context:
- Bipolar disorder is a chronic mental health condition characterized by mood swings.
- The depressive phase of bipolar disorder presents significant challenges for treatment.
- Selective serotonin reuptake inhibitors (SSRIs) are commonly used in psychiatric treatment.
Purpose:
- To evaluate the efficacy and tolerability of fluoxetine in patients with bipolar disorder during the depressive phase.
- To assess the impact of fluoxetine on depressive symptoms using standardized psychometric scales.
Summary:
- Sixty patients diagnosed with bipolar disorder in the depressive phase received fluoxetine (20-60 mg/day) for 8 weeks.
- Therapeutic efficacy was assessed using the Hamilton Depression Rating Scale (HAM-D), SCL-90, and Clinical Global Impression (CGI) at multiple time points.
- A significant reduction in HAM-D scores (over 50%) was observed in 70% of patients by the end of the study.
- Fluoxetine was found to be effective in treating bipolar depression, with 76% of patients reporting good to very good tolerability and experiencing mild, rapidly resolving side effects.
Impact:
- This study supports fluoxetine as an effective treatment option for the depressive phase of bipolar disorder.
- The findings highlight the potential for fluoxetine to improve patient outcomes and quality of life.
- The good tolerability profile suggests fluoxetine can be a viable therapeutic choice with minimal adverse effects.